Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMEA 8 Is Kaput, But A Would-Be Partner Moves On With Wellspring

This article was originally published in Start Up

Executive Summary

Two months ago, CMEA was touting its upcoming eighth fund and two new partners with a string of early-stage biotech successes on their resumes. The fund is now dissolved, but one would-be CMEA 8 partner has moved on with a new asset-centric incubator.

You may also be interested in...



Atlas, CMEA Test New Biotech Model

Two high-profile VCs, CMEA Capital and Atlas Venture, are trying their hands at asset financing, an investment strategy that prioritizes single drug programs over companies and is becoming, at least theoretically, possible to do in a more systematic way. That's because big drug companies have cut internal R&D staff, often in drastic measure, and they want someone to share the development risk of drugs now sitting idle on their shelves.

It's Apples Versus Oranges in the PI3 Kinase Race

Someone seeking a clinical space that offers a great deal of activity and anticipation, and where the major developments and dealmaking remain around the corner, would have to look no further than the PI3 kinase area. Early bets placed on PI3K pan-selective inhibitors may pay off, but smart money lately has been focused on isoform-selective inhibition of this signaling pathway implicated in cancer, inflammation, and autoimmune disease. In this issue, we profile three emerging companies hoping to succeed in developing PI3K inhibitors for diverse clinical applications: Arno Therapeutics, Intellikine, and Paloma Pharmaceuticals.

AAVLife: Another Gene Therapy Effort To Treat Friedreich's Ataxia

With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC092439

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel